Pharmaquinone

Pharmaquinone is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics for mitochondrial diseases and disorders characterized by oxidative stress. The company's lead program, vatiquinone (formerly PQ-110 or EPI-743), is a potent redox-active quinone designed to improve mitochondrial bioenergetics and inhibit ferroptosis by targeting 15-lipoxygenase. Its primary clinical focus has been Leber's Hereditary Optic Neuropathy (LHON), a rare genetic condition leading to rapid and permanent vision loss. Founded by experts in redox chemistry, Pharmaquinone leveraged a specialized platform to address unmet needs in rare pediatric and adult neurological diseases. The company was acquired by PTC Therapeutics, which has integrated the quinone pipeline into its broader orphan drug development portfolio.